lorazepam and Epilepsy, Reflex

lorazepam has been researched along with Epilepsy, Reflex in 3 studies

Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.

Epilepsy, Reflex: A subtype of epilepsy characterized by seizures that are consistently provoked by a certain specific stimulus. Auditory, visual, and somatosensory stimuli as well as the acts of writing, reading, eating, and decision making are examples of events or activities that may induce seizure activity in affected individuals. (From Neurol Clin 1994 Feb;12(1):57-8)

Research

Studies (3)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06372865

(NCT02564029)
Timeframe: Pre-dose, 1, 2, 3, 4 and 6 hours post-dose

Maximum Plasma Concentration (Cmax) of PF-06372865

(NCT02564029)
Timeframe: 1, 2, 4 and 6 hours post-dose

Number of Participants With Clinically Significant Change From Baseline in Blood Pressure and Pulse Rate

(NCT02564029)
Timeframe: 17 weeks

Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings

(NCT02564029)
Timeframe: 17 weeks

Number of Participants With Clinically Significant Laboratory Test Abnormalities

Safety laboratory tests included hematological, clinical chemistry (serum) and urinalysis safety tests. (NCT02564029)
Timeframe: 17 weeks

The Standardized Photosensitivity Range (SPR) in the Subject's Most Sensitive Eye Condition

The SPR was defined as the number of frequency steps between and including the lower and upper bound at which a generalized electroencephalogram (EEG) epileptiform activity had occurred, whereby subjects were exposed to 14 different frequencies ranging from 2 to 60 flashes per second. The SPR is then an integer score that ranges from 0 to 14 with lower scores representing better outcomes. The primary outcome measure was based on the average Least Squares Mean (LSmean) effect over the first 6 hours postdose. (NCT02564029)
Timeframe: Pre-dose, 1, 2, 4 and 6 hours post-dose

Time for Cmax (Tmax) of PF-06372865

(NCT02564029)
Timeframe: 1, 2, 4 and 6 hours post-dose

Number of Participants With Treatment-emergent Adverse Events (AEs)

The all causalities treatment-emergent AEs by System Organ Class and Preferred Term in >5% of subjects. AEs included serious AEs and non-serious AEs. (NCT02564029)
Timeframe: 19 weeks

Plasma Concentration of Lorazepam

(NCT02564029)
Timeframe: 1, 2, 3, 4 and 6 hours post-dose

The Percentage of Participants With Complete Suppression, Partial Response, and no Response to Intermittent Photic Stimulation (IPS)

Complete suppression: SPR = 0 in all three eye conditions at the same time point. Partial response: A reduction in SPR of at least 3 units from baseline for at least 3 time points, and no time points with at least 3 units of increase, in the most sensitive eye condition; without meeting the complete suppression definition. No response: Did not meet complete suppression or partial response definitions. (NCT02564029)
Timeframe: Pre-dose, 1, 2, 4 and 6 hours post-dose

The SPR in the Eye Closure, Eyes Closed, and Eyes Open Condition

The SPR was defined as the number of frequency steps between and including the lower and upper bound at which a generalized electroencephalogram (EEG) epileptiform activity had occurred, whereby subjects were exposed to 14 different frequencies ranging from 2 to 60 flashes per second. The SPR is then an integer score that ranges from 0 to 14 with lower scores representing better outcomes. The outcome measure was based on the average Least Squares Mean (LSmean) effect over the first 6 hours postdose. (NCT02564029)
Timeframe: Pre-dose, 1, 2, 4 and 6 hours post-dose

Trials

1 trial available for lorazepam and Epilepsy, Reflex

Other Studies

2 other studies available for lorazepam and Epilepsy, Reflex